A Phase 1/2a clinical trial testing VO659, Vico Therapeutics’ experimental therapy, in people with Huntington’s disease and other hereditary neurological disorders caused by a similar type of mutation has dosed the first patient. “We are encouraged by the continued progress of our development program and very pleased to…
“Do you ever feel like Huntington’s disease [HD] is the villain in the movie of our lives?” my wife, Jill, asked me recently. My wife and I live in a neighborhood with many trees and little light. As I arrived home after work one day last month, darkness greeted…
The last patient has completed the final visit in the Phase 3 PROOF-HD trial testing oral pridopidine for Huntington’s disease. That means that the study’s main placebo-controlled part is done, according to Prilenia Therapeutics, pridopidine’s developer, which sponsored the nearly 18-month-long trial. Now, the first data are…
I am sitting up in a hospital bed, trying to write this week’s column. I have an IV in my left arm that is attached to a bag full of antibiotics and steroids. As I start to bring my hand to where the needle is held in place by medical…
Thirteen years ago, my good friend Matt Ellison and I started to form what is now the Huntington’s Disease Youth Organization (HDYO). Matt and I both grew up with a parent who had Huntington’s disease (HD), so our mission with the nonprofit was to support, educate, and…
Higher levels of healthy and mutant huntingtin protein in saliva, but not in blood, are significantly associated with worse motor symptoms of Huntington’s disease, a study showed. According to the investigators, these findings support the use of noninvasive saliva tests to monitor Huntington’s progression and predict clinical outcomes —…
The other day, I heard what every husband wants to hear from his wife: “Honey, I love you, but you’re being ridiculous.” The day had started off uneventfully. It was a Saturday morning, and I woke up early to watch a soccer game on TV. The earlier the better, since…
The biopharmaceutical UCB and Aitia have joined forces to accelerate the development of a novel Huntington’s disease treatment. The collaboration will harness Aitia’s artificial intelligence (AI) technology to identify new targets and therapies for Huntington’s that will be further validated using UCB’s expertise in treatment research and…
My marriage has always been a partnership. I have strengths where my wife, Jill, has weaknesses, and vice versa — until Huntington’s disease (HD) started affecting her mental state and abilities, that is. Jill, who was diagnosed with HD in 2018, likes to say that the…
I recently watched a webinar hosted by the Huntington’s Disease Society of America that highlighted the new Roche/Genentech clinical study, GENERATION HD2 (NCT05686551), which is testing tominersen in people with Huntington’s disease (HD). I was enthused to hear all of the questions from the community that…
Get regular updates to your inbox.
